163 related articles for article (PubMed ID: 17322463)
1. Adalimumab in the therapy of uveitis in childhood.
Mansour AM
Br J Ophthalmol; 2007 Mar; 91(3):274-6. PubMed ID: 17322463
[TBL] [Abstract][Full Text] [Related]
2. Adalimumab (Humira™): a promising monoclonal anti-tumor necrosis factor alpha in ophthalmology.
Neri P; Zucchi M; Allegri P; Lettieri M; Mariotti C; Giovannini A
Int Ophthalmol; 2011 Apr; 31(2):165-73. PubMed ID: 21287227
[TBL] [Abstract][Full Text] [Related]
3. Adalimumab for sight-threatening uveitis in Behçet's disease.
Mushtaq B; Saeed T; Situnayake RD; Murray PI
Eye (Lond); 2007 Jun; 21(6):824-5. PubMed ID: 16601736
[TBL] [Abstract][Full Text] [Related]
4. Expert panel recommendations for the use of anti-tumor necrosis factor biologic agents in patients with ocular inflammatory disorders.
Levy-Clarke G; Jabs DA; Read RW; Rosenbaum JT; Vitale A; Van Gelder RN
Ophthalmology; 2014 Mar; 121(3):785-96.e3. PubMed ID: 24359625
[TBL] [Abstract][Full Text] [Related]
5. Treatment of chronic noninfectious uveitis in children--the trend toward tumor necrosis factor-alpha inhibition.
Cunningham ET
J AAPOS; 2013 Oct; 17(5):451-3. PubMed ID: 24160960
[No Abstract] [Full Text] [Related]
6. Anti-TNF-α agents for refractory cystoid macular edema associated with noninfectious uveitis.
Schaap-Fogler M; Amer R; Friling R; Priel E; Kramer M
Graefes Arch Clin Exp Ophthalmol; 2014 Apr; 252(4):633-40. PubMed ID: 24366669
[TBL] [Abstract][Full Text] [Related]
7. Adalimumab therapy for refractory childhood uveitis.
Bravo-Ljubetic L; Peralta-Calvo J; Noval S; Pastora-Salvador N; Abelairas-Gómez J; Merino R
J AAPOS; 2013 Oct; 17(5):456-9. PubMed ID: 24160962
[TBL] [Abstract][Full Text] [Related]
8. Author reply: To PMID 24359625.
Read RW; Levy-Clarke G; Jabs DA; Rosenbaum JT; Vitale A; Van Gelder RN
Ophthalmology; 2014 Oct; 121(10):e58-9. PubMed ID: 25015217
[No Abstract] [Full Text] [Related]
9. Adalimumab therapy for refractory uveitis: a pilot study.
Callejas-Rubio JL; Sánchez-Cano D; Serrano JL; Ortego-Centeno N
J Ocul Pharmacol Ther; 2008 Dec; 24(6):613-4; author reply 614. PubMed ID: 19049264
[No Abstract] [Full Text] [Related]
10. Treatment of uveitis and ankylosing spondylitis refractory to three tumor necrosis factor alpha inhibitors drugs with golimumab.
Chaparro Sanabria JA; Bautista Molano W; Valle Oñate R
Reumatol Clin (Engl Ed); 2020; 16(1):64-65. PubMed ID: 29472171
[No Abstract] [Full Text] [Related]
11. Infliximab and adalimumab for uveitis.
Martel JN; Esterberg E; Nagpal A; Acharya NR
Ocul Immunol Inflamm; 2012 Feb; 20(1):18-26. PubMed ID: 22324897
[TBL] [Abstract][Full Text] [Related]
12. [Research update of anti-TNF-α biologic agents in the treatment of uveitis].
Fan F; Zhou M; Luo Y
Zhonghua Yan Ke Za Zhi; 2013 Mar; 49(3):285-8. PubMed ID: 23866712
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of switching to adalimumab in a patient with refractory uveitis of Behçet's disease to infliximab.
Leccese P; Latanza L; D'Angelo S; Padula A; Olivieri I
Clin Exp Rheumatol; 2011; 29(4 Suppl 67):S93. PubMed ID: 21813069
[No Abstract] [Full Text] [Related]
14. Re: Levy-Clarke et al.: Expert panel recommendations for the use of anti-tumor necrosis factor biologic agents in patients with ocular inflammatory disorders (Ophthalmology 2014;121:785-96).
Onal S; Tugal-Tutkun I
Ophthalmology; 2014 Oct; 121(10):e57-8. PubMed ID: 25064722
[No Abstract] [Full Text] [Related]
15. Anti-inflammatory treatment of uveitis with biologicals: new treatment options that reflect pathogenetic knowledge of the disease.
Heiligenhaus A; Thurau S; Hennig M; Grajewski RS; Wildner G
Graefes Arch Clin Exp Ophthalmol; 2010 Nov; 248(11):1531-51. PubMed ID: 20737162
[TBL] [Abstract][Full Text] [Related]
16. Clinical experience with adalimumab in the treatment of ocular Behçet disease.
Bawazeer A; Raffa LH; Nizamuddin SH
Ocul Immunol Inflamm; 2010 Jun; 18(3):226-32. PubMed ID: 20482404
[TBL] [Abstract][Full Text] [Related]
17. Adalimumab therapy for childhood uveitis.
Vazquez-Cobian LB; Flynn T; Lehman TJ
J Pediatr; 2006 Oct; 149(4):572-5. PubMed ID: 17011337
[TBL] [Abstract][Full Text] [Related]
18. Infliximab therapy for refractory uveitis: 2-year results of a prospective trial.
Suhler EB; Smith JR; Giles TR; Lauer AK; Wertheim MS; Kurz DE; Kurz PA; Lim L; Mackensen F; Pickard TD; Rosenbaum JT
Arch Ophthalmol; 2009 Jun; 127(6):819-22. PubMed ID: 19506209
[No Abstract] [Full Text] [Related]
19. Anti-TNF therapy for juvenile idiopathic arthritis-related uveitis.
Semeraro F; Arcidiacono B; Nascimbeni G; Angi M; Parolini B; Costagliola C
Drug Des Devel Ther; 2014; 8():341-8. PubMed ID: 24711694
[TBL] [Abstract][Full Text] [Related]
20. Response of pediatric uveitis to tumor necrosis factor-α inhibitors.
Lerman MA; Burnham JM; Chang PY; Daniel E; Foster CS; Hennessy S; Jabs DA; Joffe MM; Kaçmaz RO; Levy-Clarke GA; Mills MD; Nussenblatt RB; Rosenbaum JT; Suhler EB; Thorne JE; Kempen JH
J Rheumatol; 2013 Aug; 40(8):1394-403. PubMed ID: 23818712
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
